Import substitution development strategy

(redirected from ISI)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.

Import substitution development strategy

A development strategy followed by many Latin American countries and other LDCs that emphasize import substitution-accomplished through protectionism-as the route to economic growth.

Import Substitution Development Strategy

A development strategy whereby a government restricts or forbids the import of industrial material and subsidizes local material. For example, a country may not allow the import of refined oil and instead encourage development of local oil refineries. The idea behind this strategy is to make a less developed country less dependent on international assistance and foreign direct investment until such time as it is can absorb investment more easily and also trade its own products. This development strategy was followed in Latin America and some other regions for most of the mid and late 20th century. It has its theoretical foundations in Keynesian economics, though some analysts have claimed that each nation industrializing after the United Kingdom has followed some form of import substitution.
Mentioned in ?
References in periodicals archive ?
Alexander Eiriksson, President of SecurStore, said, "The centralized backup architecture of Asigra software enabled us to fulfill the primary requirement ISI had, which was to have central control of the backup on an international scale.
Since 1992, ISI has pioneered innovative electronic submission and document management tools, earning an unprecedented reputation of delivering exacting quality, while improving their clients' speed-to-market timeliness, and obtaining regulatory approval for new medicines.
The compact ISIS 5 module, which is sixty percent smaller than previous SensArray data acquisition modules, acquires temperature data from SensArray Process Probe instrumented wafers, with up to 17 sensors.
Isis Pharma will receive total milestone payments of $50 million from Glaxo for the development of ISIS-TTR.
iSis is available in two sizes, a standard version for A4+ or letter size and an XL version for A3+ or tabloid charts.
About Isis Intellectual Property (IP) Licensed to Alnylam for RNAi Therapeutics
What: Isis Pharmaceuticals' Ibis Division Analyst Day Webcast.
Following the announcement of a manufacturing and distribution agreement between Isis Pharmaceuticals and Bruker Daltonics earlier this year, the companies have taken the next important step towards commercialization of the Ibis T5000 biosensor system by entering the large European markets.
What: Isis Pharmaceuticals' Analyst/Investor Webcast Presentation
DUBLIN, Ireland -- The Isis Pharmaceuticals (NASDAQ:ISIS) Corporate Conference Call took place on 10-Feb-06 8:30am ET.